Nebivolol reduces central blood pressure in stage I hypertensive patients: Experimental single cohort study;Nebivolol reduz pressão arterial central em pacientes hipertensos estágio I: Estudo experimental de coorte única

Sao Paulo Medical Journal

Volumn 132, Issue 5, 2014, Pages 290-296

  Vaz de Melo, Renan Oliveira ^a   Giollo Júnior, Luiz Tadeu ^a   Martinelli, Débora Dada ^a   Moreno Júnior, Heitor ^b   Mota Gomes, Marco Antônio ^c   Cipullo, José Paulo ^d   Yugar Toledo, Juan Carlos ^d   Vilela Martin, José Fernando ^e  

^a HOSPITAL DE BASE   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSIDADE ESTADUAL DE CIÊNCIAS DA SAÚDE DE ALAGOAS   (Brazil)

^d Department of Internal Medicine   (Brazil)

^e Department of Internal Medicine ^*  (Brazil)

Author keywords

Adrenergic beta antagonists; Arterial pressure; Hypertension; Pulse wave analysis; Vasodilator agents

Indexed keywords

NEBIVOLOL; ANTIHYPERTENSIVE AGENT; BENZOPYRAN DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE; BRACHIAL ARTERY; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; MALE; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TONOMETRY; COHORT ANALYSIS; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; OUTPATIENT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; BRACHIAL ARTERY; COHORT STUDIES; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OUTPATIENTS; PULSE WAVE ANALYSIS;

EID: 84920988763     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-3180.2014.1325704     Document Type: Article

References (30)

1. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25.
2. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50(1):197-203.
3. Roman MJ, Devereux RB, Kizer JR, et al. High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study. J Am Coll Cardiol. 2009;54(18):1730-4.
4. Protogerou AD, Papaioannou TG, Blacher J, et al. Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target? J Hypertens. 2007;25(2):265-72.
5. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;45(5):907-13.
6. Polónia J, Barbosa L, Silva JA, Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit. 2010;15(5):235-9.
7. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21(6):663-7.
8. Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57(6):1122-8.
9. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009;5(1):353-60.
10. Boutouyrie P, Achouba A, Trunet P, Laurent S; EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55(6):1314-22.
11. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension. 2004;44(2):112-6.
12. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl. 2004;1:17-32.
13. Ignarro LJ, Byrns RE, Trinh K, Sisodia M, Buga GM. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide-and cyclic GMP-dependent mechanisms. Nitric Oxide. 2002;7(2):75-82.
14. Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-generation betaadrenergic blocker. Ann Pharmacother. 2006;40(7-8):1353-60.
15. de Groot AA, Mathy MJ, van Zwieten PA, Perters SL. Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol. 2003;42(2):232-6.
16. Gielen W, Cleophas TJ, Agrawal R. Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006;44(8):344-57.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
18. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87.
19. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588-605.
20. Vaz-de-Melo RO, Pimenta AG, Giollo Júnior LT, et al. Fatores associados ao aumento no índice de incremento de pressão radial em indivíduos hipertensos [Factors associated with increased radial augmentation index in hypertensive individuals]. Arq Bras Cardiol. 2011;97(3):241-8.
21. Safar ME, Jankowski P. Central blood pressure and hypertension: role in cardiovascular risk assessment. Clin Sci (Lond). 2009;116(4):273-82.
22. Agabiti-Rosei E, Mancia G, O'Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50(1):154-160.
23. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17(2):118-23.
24. Schneider MP, Delles C, Klingbeil AU, et al. Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. J Renin Angiotensin Aldosterone Syst. 2008;9(1):49-56.
25. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet. 2005;366(9496):1545-53.
26. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50(7):563-72.
27. Ram CV. Beta-blockers in hypertension. Am J Cardiol. 2010; 106(12):1819-25.
28. Vitale C, Marazzi G, Iellamo F, et al. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol. 2012;155(2):279-84.
29. Kamran H, Salciccioli L, Bastien C, et al. Effect of beta blockers on central aortic pressure in African-Americans. J Am Soc Hypertens. 2011;5(2):94-101.
30. Cockcroft J. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient. Vasc Health Risk Manag. 2007; 3(6):909-17.